These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1671 related items for PubMed ID: 17488680

  • 21. [Thalassemia: therapeutic hopes carried by hepcidin].
    Vaulont S, Labie D.
    Med Sci (Paris); 2011 May; 27(5):473-5. PubMed ID: 21609665
    [No Abstract] [Full Text] [Related]

  • 22. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S, Ramos P, Marongiu MF, Melchiori L, Breda L, Guy E, Muirhead K, Rao N, Roy CN, Andrews NC, Nemeth E, Follenzi A, An X, Mohandas N, Ginzburg Y, Rachmilewitz EA, Giardina PJ, Grady RW, Rivella S.
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [Abstract] [Full Text] [Related]

  • 23. What regulates hepcidin in poly-transfused β-Thalassemia Major: erythroid drive or store drive?
    Chauhan R, Sharma S, Chandra J.
    Indian J Pathol Microbiol; 2014 Dec; 57(1):39-42. PubMed ID: 24739829
    [Abstract] [Full Text] [Related]

  • 24. Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression.
    Camberlein E, Zanninelli G, Détivaud L, Lizzi AR, Sorrentino F, Vacquer S, Troadec MB, Angelucci E, Abgueguen E, Loréal O, Cianciulli P, Lai ME, Brissot P.
    Haematologica; 2008 Jan; 93(1):111-5. PubMed ID: 18166793
    [Abstract] [Full Text] [Related]

  • 25. Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy.
    Zarghamian P, Azarkeivan A, Arabkhazaeli A, Mardani A, Shahabi M.
    BMC Med Genet; 2020 Apr 08; 21(1):75. PubMed ID: 32268883
    [Abstract] [Full Text] [Related]

  • 26. Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in β-thalassemia.
    Xiao X, Moschetta GA, Xu Y, Fisher AL, Alfaro-Magallanes VM, Dev S, Wang CY, Babitt JL.
    Blood; 2023 Jan 26; 141(4):422-432. PubMed ID: 36322932
    [Abstract] [Full Text] [Related]

  • 27. Iron Status in Newly Diagnosed β-Thalassemia Major: High Rate of Iron Status due to Erythropoiesis Drive.
    Susanah S, Rakhmilla LE, Ghozali M, Trisaputra JO, Moestopo O, Sribudiani Y, Idjradinata PS, Maskoen AM.
    Biomed Res Int; 2021 Jan 26; 2021():5560319. PubMed ID: 33954177
    [Abstract] [Full Text] [Related]

  • 28. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
    Musallam KM, Cappellini MD, Wood JC, Taher AT.
    Blood Rev; 2012 Apr 26; 26 Suppl 1():S16-9. PubMed ID: 22631036
    [Abstract] [Full Text] [Related]

  • 29. A tincture of hepcidin cures all: the potential for hepcidin therapeutics.
    Bartnikas TB, Fleming MD.
    J Clin Invest; 2010 Dec 26; 120(12):4187-90. PubMed ID: 21099105
    [Abstract] [Full Text] [Related]

  • 30. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait.
    Jones E, Pasricha SR, Allen A, Evans P, Fisher CA, Wray K, Premawardhena A, Bandara D, Perera A, Webster C, Sturges P, Olivieri NF, St Pierre T, Armitage AE, Porter JB, Weatherall DJ, Drakesmith H.
    Blood; 2015 Jan 29; 125(5):873-80. PubMed ID: 25519750
    [Abstract] [Full Text] [Related]

  • 31. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.
    Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL.
    Nat Med; 2007 Sep 29; 13(9):1096-101. PubMed ID: 17721544
    [Abstract] [Full Text] [Related]

  • 32. Exploring the role of hepcidin, an antimicrobial and iron regulatory peptide, in increased iron absorption in beta-thalassemia.
    Breda L, Gardenghi S, Guy E, Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Giardina PJ, Grady RW, Rivella S.
    Ann N Y Acad Sci; 2005 Sep 29; 1054():417-22. PubMed ID: 16339690
    [Abstract] [Full Text] [Related]

  • 33. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores.
    Tony S, Daar S, Elshinawy M, Al-Zadjaly S, Al-Khabori M, Wali Y.
    Pediatr Hematol Oncol; 2012 Sep 29; 29(6):579-84. PubMed ID: 22839111
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M, Arandi N, Haghpanah S, Ansari S, Azarkeyvan A, Bordbar M, Safaei S.
    Hemoglobin; 2015 Sep 29; 39(5):327-9. PubMed ID: 26114738
    [Abstract] [Full Text] [Related]

  • 35. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
    Mirlohi MS, Yaghooti H, Shirali S, Aminasnafi A, Olapour S.
    Ann Hematol; 2018 Apr 29; 97(4):679-684. PubMed ID: 29318368
    [Abstract] [Full Text] [Related]

  • 36. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis.
    Gutschow P, Schmidt PJ, Han H, Ostland V, Bartnikas TB, Pettiglio MA, Herrera C, Butler JS, Nemeth E, Ganz T, Fleming MD, Westerman M.
    Haematologica; 2015 Feb 29; 100(2):167-77. PubMed ID: 25425686
    [Abstract] [Full Text] [Related]

  • 37. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
    Al-Khabori M, Bhandari S, Al-Rasadi K, Mevada S, Al-Dhuhli H, Al-Kemyani N, Daar S.
    Hemoglobin; 2014 Feb 29; 38(5):365-8. PubMed ID: 25074643
    [Abstract] [Full Text] [Related]

  • 38. Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major.
    Wahidiyat PA, Wijaya E, Soedjatmiko S, Timan IS, Berdoukas V, Yosia M.
    Blood Cells Mol Dis; 2019 Jul 29; 77():67-71. PubMed ID: 30978615
    [Abstract] [Full Text] [Related]

  • 39. Iron homeostasis during transfusional iron overload in beta-thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression.
    Jenkins ZA, Hagar W, Bowlus CL, Johansson HE, Harmatz P, Vichinsky EP, Theil EC.
    Pediatr Hematol Oncol; 2007 Jun 29; 24(4):237-43. PubMed ID: 17613866
    [Abstract] [Full Text] [Related]

  • 40. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C.
    Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H, Kobayashi Y, Iwasa M, Watanabe S, Adachi Y, Kaito M.
    Mol Med; 2007 Jun 29; 13(1-2):97-104. PubMed ID: 17515961
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 84.